I'd feel better if the climate for financing was easier. They hinted broadly in the last CC that they had projects worth pursuing that were being held back because they considered it necessary to stay GAAP profitable.
It was amusing that with the corporate pitch being that Volcano products make stenting more cost-effective, the stock got whacked along with the stent makers when there was a news story about push-back against excessive use of medical devices.
I only know what management says in public. These people seem to be having entirely too much fun, but they've deliverd as promised to date. They say that the reason they're holding back is to keep the funding internal. They also say that they WANT hospitals to change the way they run things (in particular, device-by-device review--"Why did you place THAT stent, and did it perform as you wanted it to?").